Escalating and de-escalating treatment in HER2-positive early breast cancer
about
Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway.Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial.Prognostic value and clinicopathological significance of serum- and tissue-based cytokeratin 18 express level in breast cancer: a meta-analysis.3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis.Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs
P2860
Escalating and de-escalating treatment in HER2-positive early breast cancer
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Escalating and de-escalating treatment in HER2-positive early breast cancer
@ast
Escalating and de-escalating treatment in HER2-positive early breast cancer
@en
Escalating and de-escalating treatment in HER2-positive early breast cancer
@nl
type
label
Escalating and de-escalating treatment in HER2-positive early breast cancer
@ast
Escalating and de-escalating treatment in HER2-positive early breast cancer
@en
Escalating and de-escalating treatment in HER2-positive early breast cancer
@nl
prefLabel
Escalating and de-escalating treatment in HER2-positive early breast cancer
@ast
Escalating and de-escalating treatment in HER2-positive early breast cancer
@en
Escalating and de-escalating treatment in HER2-positive early breast cancer
@nl
P1476
Escalating and de-escalating treatment in HER2-positive early breast cancer
@en
P2093
Heikki Joensuu
P356
10.1016/J.CTRV.2016.11.002
P407
P577
2016-11-10T00:00:00Z